Advertisement

Clinical and Translational Imaging

, Volume 7, Issue 1, pp 45–60 | Cite as

PET in brain tumors

  • Davide DonnerEmail author
  • Umberto Rozzanigo
  • Dante Amelio
  • Silvio Sarubbo
  • Daniele Scartoni
  • Lorena Picori
  • Maurizio Amichetti
  • Franco Chioffi
  • Franca Chierichetti
Pictorial Essay
  • 124 Downloads
Part of the following topical collections:
  1. Neuroimaging

Abstract

Purpose

The aim of this Pictorial Essay is to illustrate the metabolic aspect of PET (positron emission tomography) imaging in relation to conventional and advanced MR (magnetic resonance) of brain neoplasms.

Materials

10 patients, who performed PET–CT with amino acid tracers and/or FDG were selected from a series of more than 250 cases from a single institution. The selection was made to illustrate and discuss each of the indications reported in the European guidelines. Fusion imaging was obtained merging PET–CT with MR T1-CE (contrast enhanced) and/or T2/FLAIR sequences. The SUVmax of the lesion and the SUVmax lesion to SUVmax background ratio were evaluated. The lesion uptake was also assessed using a five-point visual scale with a range from − 2 to + 2 in relation to basal ganglia uptake. The Hospital Information System (HIS) and the proton therapy data archives have been used for clinical history. For each case, the critical issues were described and the physiopathological correlations were provided to explain the imaging findings.

Conclusions

The complexity of illustrated cases demonstrates the need for a multidisciplinary board evaluation to reach a more accurate diagnosis.

Keywords

Brain lesions Differential diagnosis PET–CT imaging Advanced MR 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A (2012) Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48(10):1532–1542.  https://doi.org/10.1016/j.ejca.2011.12.013 (Epub 2012 Jan 7) PubMedGoogle Scholar
  2. 2.
    Linee Guida delle Neoplasie Cerebrali. AIOM (Associazione Italiana Oncologia Medica) Edizione 2017Google Scholar
  3. 3.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol.  https://doi.org/10.1007/s00401-016-1545-1 Google Scholar
  4. 4.
    Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, Rovira A, Weller M, Law M (2012) MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR 33(5):803–817.  https://doi.org/10.3174/ajnr.A2640 PubMedGoogle Scholar
  5. 5.
    Al-Okaili RN, Krejza J, Wang S, Woo H, Melhem ER (2006) Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 26(Suppl 1):S173–S189PubMedGoogle Scholar
  6. 6.
    Thust SC, Heiland S, Falini A, Jäger HR, Waldman AD, Sundgren PC, Godi C, Katsaros VK, Ramos A, Bargallo N, Vernooij MW, Yousry T, Bendszus M, Smits M (2018) Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol 28(8):3306–3317PubMedGoogle Scholar
  7. 7.
    Pyka T, Gempt J, Bette S, Ringel F, Förster S (2017) Positron emission tomography and magnetic resonance spectroscopy in cerebral gliomas. Clin Transl Imaging 5(2):151–158Google Scholar
  8. 8.
    Chen W, Silverman DHS, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMedGoogle Scholar
  9. 9.
    Gulyás B, Halldin C (2012) New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 56(2):173–190PubMedGoogle Scholar
  10. 10.
    A joint RANO/EANO/EANM practice guideline/SNMMI procedure standard for imaging of gliomas using PET with radiolabeled amino acids and [18F]FDG: version 1.0Google Scholar
  11. 11.
    Filss CP, Cicone F, Jon Shah N, Galldiks N, Langen K-J (2017) Amino acid PET and MR perfusion imaging in brain tumours. Clin Transl Imaging 5(3):209–223PubMedGoogle Scholar
  12. 12.
    Oehlke O, Grosu AL (2016) A-L.PET/MRI and brain tumors: focus on radiation oncology treatment planning. Clin Transl Imaging 2(5):159–167Google Scholar
  13. 13.
    Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199–1208PubMedGoogle Scholar
  14. 14.
    Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougère C (2015) Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 56:9–15PubMedGoogle Scholar
  15. 15.
    Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12):1933–1942PubMedGoogle Scholar
  16. 16.
    Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen K-J, Galldiks N (2018) Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging 45:443–451PubMedGoogle Scholar
  17. 17.
    Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W (2010) Correlation of 6-18F-fluoro-l-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 51:1532–1538PubMedGoogle Scholar
  18. 18.
    Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, Smith J, Rose S (2015) Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma. Nucl Med Biol 42:788–795PubMedGoogle Scholar
  19. 19.
    Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radio- therapy target delineation: results of a prospective pilot study. Neuro Oncol 15(8):1058–1067PubMedGoogle Scholar
  20. 20.
    Takahashi Y, Akahane T, Yamamoto D, Nakamura H, Sawa H, Nitta K, Ide W, Hashimoto I, Kamada H (2014) Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas. Mol Clin Oncol 2:525–529PubMedGoogle Scholar
  21. 21.
    Chiavazza C, Pellerino A, Ferrio F, Cistaro A, Soffietti R, Rudà R (2018) Primary CNS lymphomas: challenges in diagnosis and monitoring. BioMed Res Int.  https://doi.org/10.1155/2018/3606970 PubMedGoogle Scholar
  22. 22.
    Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T (2013) 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. BioMed Res Int.  https://doi.org/10.1155/2013/247152 PubMedGoogle Scholar
  23. 23.
    Maza S, Buchert R, Brenner W, Munz DL, Thiel E, Korfel A, Kiewe P (2013) Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma. Radiol Oncol 47(2):103–110PubMedGoogle Scholar
  24. 24.
    Dadone-Montaudié B, Ambrosetti D, Dufour M, Darcourt J, Almairac F, Coyne J, Virolle T, Humbert O, Burel-Vandenbros F (2017) [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One 22 12(9):e0184625.  https://doi.org/10.1371/journal.pone.0184625 Google Scholar
  25. 25.
    Freyschlag CF, Krieg SM, Kerschbaumer J, Pinggera D, Forster MT, Cordier D, Rossi M, Miceli G, Roux A, Reyes A, Sarubbo S, Smits A, Sierpowska J, Robe PA, Rutten GJ, Santarius T, Matys T, Zanello M, Almairac F, Mondot L, Jakola AS, Zetterling M, Rofes A, von Campe G, Guillevin R, Bagatto D, Lubrano V, Rapp M, Goodden J, De Witt Hamer PC, Pallud J, Bello L, Thomé C, Duffau H, Mandonnet E (2018) Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging. J Neurooncol 139:699–711.  https://doi.org/10.1007/s11060-018-2916-3 PubMedGoogle Scholar
  26. 26.
    Cendes F, Theodore WH, Brinkmann BH, Sulc V, Cascino GD (2016) Neuroimaging of epilepsy. Handb Clin Neurol 136:985–1014PubMedGoogle Scholar
  27. 27.
    Lupo JM, Nelson SJ (2014) Advanced MR imaging methods for planning and monitoring radiation therapy in patients with high grade glioma. Semin Radiat Oncol 24(4):248–258PubMedGoogle Scholar
  28. 28.
    Walker J, Ruzevick J, Malayeri AA, Rigamonti D, Lim M, Redmond KJ, Kleinberg L (2014) Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol 10(7):1277–1297PubMedGoogle Scholar
  29. 29.
    Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala L, Benz MR, Ak Buck, Phelps ME, Chen W (2014) Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol 16:603–609PubMedGoogle Scholar
  30. 30.
    Hatzoglou V, Ulaner GA, Zhang Z, Beal K, Holodny AI, Young RJ (2013) Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor. Clin Imaging 37(3):451–457PubMedGoogle Scholar
  31. 31.
    Miller-Thomas MM, Benzinger TLS (2017) Neurological applications of PET/MR. Magn Reson Imaging Clin N Am 25(2):297–313PubMedGoogle Scholar
  32. 32.
    Toch SR, Poussier S, Micard E, Bertaux M, Van Der Gucht A, Chevalier E, Marie PY, Guedj E, Verger A (2018) Physiological whole-brain distribution of [18F]FDOPA uptake index in relation to age and gender: results from a voxel-based semi-quantitative analysis. Mol Imaging Biol.  https://doi.org/10.1007/s11307-018-1256-1 PubMedGoogle Scholar
  33. 33.
    Chen W (2007) Clinical applications of PET in brain tumors. J Nucl Med 48:1468–1481PubMedGoogle Scholar
  34. 34.
    Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AAF, Yong WH, Phelps ME, Chen W (2014) 18F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med 55:1–7Google Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2018

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentSanta Chiara Hospital, APSS TrentoTrentoItaly
  2. 2.Radiology DepartmentSanta Chiara Hospital, APSS TrentoTrentoItaly
  3. 3.Proton TherapyAPSS TrentoTrentoItaly
  4. 4.NeurosurgerySanta Chiara Hospital, APSS TrentoTrentoItaly

Personalised recommendations